OKYO
No price yet
Announcements
Nothing here yet
Daily updates
Nothing here yet
FDA designations
Nothing here yet
News
- OKYO Pharma enrolls the first patients in the pivotal Phase 3 trial of urcosimod for neuropathic corneal painOct 6, 2026
- OKYO Pharma received positive FDA feedback and advanced urcosimod into a global pivotal Phase 3 trial for neuropathic corneal painJul 8, 2026
- OKYO Pharma completed successful Type C meeting with FDAJan 28, 2026
- OKYO Pharma announces new data showing favorable corneal nerve outcomes in Phase 2 neuropathic corneal pain studyDec 11, 2025
- OKYO Pharma announces registration pathway with 100 patient multi-center clinical trial of Urcosimod in neuropathic corneal painSep 22, 2025